Theodore Alan Huizenga - Dec 20, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
SVP, Chief Accounting Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Dec 20, 2023
Transactions value $
$63,000
Form type
4
Date filed
1/2/2024, 04:06 PM
Previous filing
Sep 29, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +1K +4.23% $0.00 24.6K Dec 20, 2023 Direct F1
transaction RARE Common Stock Options Exercise $63K +3K +12.05% $21.00 27.9K Jan 2, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -3K -100% $0.00* 0 Jan 2, 2024 Common Stock 3K $21.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F2 Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F4 1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.